Kercheville Advisors LLC Has $549,000 Holdings in Bristol-Myers Squibb (NYSE:BMY)

Kercheville Advisors LLC grew its position in Bristol-Myers Squibb (NYSE:BMY) by 143.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,001 shares of the biopharmaceutical company’s stock after buying an additional 5,305 shares during the quarter. Kercheville Advisors LLC’s holdings in Bristol-Myers Squibb were worth $549,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Wealthspire Advisors LLC grew its position in Bristol-Myers Squibb by 0.6% during the 4th quarter. Wealthspire Advisors LLC now owns 28,679 shares of the biopharmaceutical company’s stock worth $1,622,000 after purchasing an additional 170 shares in the last quarter. Bedel Financial Consulting Inc. grew its holdings in shares of Bristol-Myers Squibb by 3.2% during the fourth quarter. Bedel Financial Consulting Inc. now owns 5,690 shares of the biopharmaceutical company’s stock valued at $340,000 after buying an additional 175 shares in the last quarter. King Wealth Management Group raised its position in Bristol-Myers Squibb by 2.6% during the fourth quarter. King Wealth Management Group now owns 7,294 shares of the biopharmaceutical company’s stock valued at $413,000 after buying an additional 182 shares during the period. Thoroughbred Financial Services LLC lifted its stake in Bristol-Myers Squibb by 1.1% in the 4th quarter. Thoroughbred Financial Services LLC now owns 17,763 shares of the biopharmaceutical company’s stock worth $1,004,000 after acquiring an additional 190 shares in the last quarter. Finally, Marcum Wealth LLC boosted its position in Bristol-Myers Squibb by 1.0% during the 1st quarter. Marcum Wealth LLC now owns 19,296 shares of the biopharmaceutical company’s stock worth $1,177,000 after acquiring an additional 193 shares during the period. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Bristol-Myers Squibb

In other news, EVP Samit Hirawat purchased 4,250 shares of the business’s stock in a transaction on Friday, April 25th. The stock was purchased at an average price of $47.58 per share, with a total value of $202,215.00. Following the acquisition, the executive vice president now directly owns 83,513 shares in the company, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Trading Down 2.2%

Shares of NYSE:BMY opened at $48.65 on Tuesday. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $63.33. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The company has a market cap of $99.01 billion, a P/E ratio of -11.01, a P/E/G ratio of 2.07 and a beta of 0.38. The stock’s 50-day moving average is $48.62 and its 200-day moving average is $54.63.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The company had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. During the same period in the previous year, the business posted ($4.40) EPS. The company’s revenue for the quarter was down 5.6% on a year-over-year basis. Equities research analysts predict that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Cantor Fitzgerald restated a “neutral” rating and set a $55.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. Wall Street Zen cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Friday, June 6th. The Goldman Sachs Group reiterated a “neutral” rating and set a $55.00 price objective (down from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Piper Sandler started coverage on Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $65.00 target price on the stock. Finally, William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $58.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.